List of Excipients in Branded Drug VANFLYTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Daiichi Sankyo Inc	VANFLYTA	quizartinib	65597-504	CELLULOSE, MICROCRYSTALLINE	2030-07-20
Daiichi Sankyo Inc	VANFLYTA	quizartinib	65597-504	HYDROXYPROPYL BETADEX	2030-07-20
Daiichi Sankyo Inc	VANFLYTA	quizartinib	65597-504	HYPROMELLOSE	2030-07-20

VANFLYTA Excipient Strategy and Commercial Opportunities in Quizartinib Formulation

Last updated: September 24, 2026

VANFLYTA is an oral quizartinib product developed by Daiichi Sankyo for newly diagnosed FLT3-ITD-positive acute myeloid leukemia. Its commercial formulation is a conventional immediate-release film-coated tablet. The main excipient opportunity is not basic tablet manufacture, which is relatively commoditized, but differentiated development around dose flexibility, food-effect control, lifecycle management, pediatric delivery, stability, and potential generic-entry barriers.

What is VANFLYTA and how is quizartinib supplied?

VANFLYTA contains quizartinib dihydrochloride, a type 1 FLT3 inhibitor. The FDA approved VANFLYTA on June 20, 2023, in combination with standard cytarabine and anthracycline induction and consolidation chemotherapy, followed by single-agent maintenance for adults with newly diagnosed AML that is FLT3-ITD positive.[1]

The product is supplied as immediate-release tablets in two strengths:

Product strength	Quizartinib content	Typical clinical role
VANFLYTA 17.7 mg	Equivalent to 17.7 mg quizartinib	Supports a 35.4 mg daily dose using two tablets
VANFLYTA 26.5 mg	Equivalent to 26.5 mg quizartinib	Supports a 53 mg daily dose using two tablets

The recommended schedule uses a 14-day induction-cycle regimen, followed by a 14-day consolidation-cycle regimen and maintenance dosing. The approved label includes a dose escalation from 35.4 mg once daily to 53 mg once daily in certain treatment phases, subject to clinical monitoring and QT-interval restrictions.[1]

This dosing architecture influences excipient and tablet-design decisions. A formulation must support precise dose adjustment, rapid and reproducible dissolution, low tablet burden, and reliable performance during intensive chemotherapy.

What excipients are used in VANFLYTA tablets?

The FDA prescribing information identifies a standard solid-oral excipient system for VANFLYTA. The tablet formulation includes the following inactive ingredients:

Excipient category	Reported excipient	Likely formulation function
Diluent and bulking agent	Mannitol	Tablet mass, mouthfeel, compressibility
Diluent and binder	Microcrystalline cellulose	Mechanical strength and compactability
Disintegrant	Croscarmellose sodium	Tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Powder flow and manufacturing consistency
Lubricant	Magnesium stearate	Ejection from compression tooling
Film former	Polyvinyl alcohol	Protective and cosmetic film coating
Opacifier and pigment	Titanium dioxide	Opacity and appearance
Coating aid	Talc	Coating process control
Colorant	Iron oxide pigment	Tablet identification and strength differentiation

The formulation is consistent with a low-complexity immediate-release oncology tablet. It does not rely on a controlled-release matrix, lipid formulation, enteric coating, amorphous solid dispersion, or specialized drug-delivery platform.[1]

The commercial value of this composition comes from manufacturing reproducibility and product performance rather than from an inherently novel excipient system. Mannitol and microcrystalline cellulose provide a familiar solid-dose platform. Croscarmellose sodium supports rapid disintegration, while colloidal silicon dioxide and magnesium stearate help control powder flow and compression.

How does the VANFLYTA excipient strategy support commercial manufacturing?

The formulation has several manufacturing advantages.

First, the excipient system uses widely available pharmaceutical-grade materials. That reduces dependence on specialized excipient suppliers and limits supply-chain concentration risk.

Second, the product is an immediate-release tablet. This generally allows conventional high-speed compression, standard film coating, and conventional blister or bottle packaging. The process does not require multiparticulate manufacture, hot-melt extrusion, spray drying, osmotic systems, or specialized capsule filling.

Third, the two-strength strategy supports dose flexibility without requiring a large product family. The 17.7 mg and 26.5 mg strengths allow the marketed dose levels to be delivered with two tablets. The approach avoids excessive tablet size while preserving a straightforward manufacturing platform.

Fourth, the film coating provides color coding and a physical barrier against handling-related defects. In oncology products, visual differentiation between strengths is important because dosing changes occur in a clinically sensitive population.

The principal process risks are ordinary but material: magnesium stearate over-lubrication can slow dissolution, croscarmellose distribution can affect disintegration, and coating variability can alter appearance, weight gain, and mechanical protection. These factors can create development and scale-up work even when the excipient list itself is conventional.

What formulation opportunities exist for VANFLYTA lifecycle management?

The strongest opportunities are modified presentations that solve clinical or commercial problems not fully addressed by the existing tablet.

Smaller tablets and lower pill burden

The approved dosing schedule can require two tablets per administration. A higher-strength tablet, if clinically and regulatorily acceptable, could reduce pill burden. This opportunity is constrained by dose flexibility, tablet size, content uniformity, and the need to preserve the approved dose-escalation scheme.

A single-tablet 35.4 mg or 53 mg presentation could have value in maintenance therapy, where patients may take quizartinib for extended periods. The commercial case would depend on whether the new presentation improves adherence or reduces dispensing complexity enough to justify development and regulatory expense.

Pediatric and dysphagia-friendly dosage forms

AML treatment includes patients who may have difficulty swallowing tablets. Potential approaches include:

• Oral suspension
• Dispersible tablet
• Orally disintegrating tablet
• Tablet for dispersion in water
• Smaller multiparticulate presentation

These formats would require careful control of quizartinib solubility, taste, dose uniformity, sedimentation, redispersibility, and chemical stability. A suspension could create new preservative, container-closure, and microbial-control requirements. An orally disintegrating tablet could require taste masking and a different superdisintegrant system.

The pediatric opportunity is commercially relevant but not automatically broad. The approved indication is adult AML, so a pediatric formulation would need a corresponding regulatory and clinical strategy rather than an excipient-only change.

Taste-masked liquid formulation

Quizartinib is a potent small molecule administered at a relatively low dose, making a liquid feasible from a dose-loading perspective. The challenge is palatability and stability. Taste masking could use polymeric coatings, ion-exchange resins, complexation, or sweetener and flavor systems.

A liquid formulation could also support patients receiving intensive chemotherapy who develop mucositis, nausea, swallowing difficulty, or gastrointestinal complications. The formulation would need to avoid excipients that create unacceptable risks in oncology patients, including excessive ethanol, propylene glycol, or high sugar loads.

Food-effect and absorption-control formulations

The FDA label instructs patients to take VANFLYTA with or without food at approximately the same time each day.[1] This creates a commercial opportunity for formulations designed to reduce variability under fed and fasted conditions.

Potential approaches include particle-size engineering, wetting agents, surfactants, solid dispersions, or alternative salt and crystal forms. Any new system would need to demonstrate bioequivalence or clinical comparability and would have to preserve the safety profile associated with quizartinib exposure and QT prolongation.

The value is potentially high because consistent exposure matters for a drug with dose-dependent cardiac risk. The development threshold is also high because a formulation that increases exposure could worsen safety risk.

Stability and packaging improvements

An improved formulation may target:

• Lower moisture uptake
• Reduced degradation during long-term storage
• Better protection from light
• Reduced tablet friability
• Lower dependence on desiccants
• Greater compatibility with automated dispensing

High-barrier blister packaging, desiccant bottles, and improved coating systems may offer near-term commercial opportunities without changing the active formulation. These approaches generally have a lower regulatory burden than a new dosage form, although packaging changes can still require stability and extractables-leachables data.

What formulation patents could protect VANFLYTA products?

Potential patent categories include:

Patent category	Possible claim scope	Commercial relevance
Composition of matter	Quizartinib molecule, salt, polymorph, or crystal form	Core exclusivity
Pharmaceutical composition	Quizartinib with specified excipients or ratios	May protect a marketed formulation
Dosage form	Immediate-release tablet, suspension, dispersible tablet, or ODT	Lifecycle protection
Manufacturing process	Granulation, compression, coating, or crystallization process	Can raise generic development costs
Stability	Formulation or package producing defined shelf life	Supports product differentiation
Method of use	Treatment of FLT3-ITD-positive AML and dosing regimens	Important for branded indication protection
Combination therapy	Quizartinib with cytarabine, anthracycline, consolidation, or maintenance	Supports the approved treatment pathway

A formulation patent is strongest when it claims a narrow but technically necessary combination of excipient ranges, dissolution criteria, stability results, and manufacturing parameters. A generic applicant may avoid a broad formulation claim by changing the diluent, disintegrant, coating, or process.

For that reason, excipient patents often provide supplementary protection rather than replacing the active-ingredient patent estate. The commercial strength of any VANFLYTA formulation patent would depend on claim breadth, written-description support, freedom to operate around alternative excipients, and the extent to which the FDA-approved product practices the claims.

When does VANFLYTA lose exclusivity?

VANFLYTA receives multiple forms of U.S. regulatory protection.

Protection	Relevant date or status
FDA approval	June 20, 2023
New chemical entity exclusivity	Expected to run for five years from approval, subject to applicable patent-challenge rules
Orphan-drug exclusivity	The product was approved for a rare disease indication and may receive seven years of indication-specific exclusivity if the statutory requirements apply
Patent protection	Determined by the issued patents and Orange Book listings, which can extend beyond regulatory exclusivity
Generic pathway	ANDA applicants may pursue approval after relevant exclusivity and patent constraints are cleared

The key commercial window is therefore longer than the five-year NCE period if orphan exclusivity or enforceable patents cover the approved use. Orphan exclusivity does not block every possible generic product in every circumstance; it is indication-specific and subject to statutory exceptions.[2]

Patent expiration dates should be assessed from the current FDA Orange Book and USPTO records. A precise generic-entry date cannot be inferred from the approval date alone.

What is the Orange Book status of VANFLYTA?

VANFLYTA is an FDA-approved small-molecule drug and is eligible for Orange Book patent listing if its sponsor has submitted patents that meet FDA listing requirements. The relevant categories may include active-ingredient, formulation, method-of-use, and drug-substance or drug-product process patents, subject to FDA listing rules.[3]

Generic applicants seeking approval before listed patent expiration may file Paragraph IV certifications. Such a filing can trigger patent litigation under the Hatch-Waxman framework if the patent holder brings an infringement action within the statutory period.[4]

The likely generic pathway is an ANDA, not a biosimilar application. Quizartinib is a chemically synthesized small molecule, so biosimilar competition is not the relevant risk category.

Which companies are likely to challenge VANFLYTA?

Potential challengers include generic oncology manufacturers with experience in high-value oral targeted therapies, such as Teva, Viatris, Sandoz, Sun Pharma, Dr. Reddy's Laboratories, Cipla, Aurobindo, and other ANDA developers. A specific Paragraph IV challenger should not be treated as confirmed without an FDA filing, court complaint, or public settlement record.

The most probable entry sequence is:

1. Patent and Orange Book review by generic developers.
2. API and formulation development using a non-infringing excipient system.
3. ANDA submission with Paragraph III or Paragraph IV certifications.
4. Possible patent litigation.
5. Launch after patent settlement, judgment, expiry, or regulatory exclusivity clearance.

Because the marketed formulation is conventional, a generic applicant may have several excipient design-around options. The more defensible barriers are likely to arise from active-ingredient patents, polymorph or salt claims, method-of-use claims, and patents tied to clinically important dosing regimens.

How strong is the VANFLYTA patent estate?

The estate should be viewed as potentially strongest around quizartinib chemistry, clinical use, and treatment sequencing, rather than around the listed excipients alone.

Estate component	Expected strength in generic litigation
Active ingredient and core chemical claims	High if unexpired and valid
Salt or polymorph claims	Moderate to high, depending on claim scope and prior art
Approved AML method of use	Moderate to high for labeled generic use
Combination and maintenance regimen claims	Moderate, with potential design-around issues
Conventional excipient composition	Low to moderate unless narrowly optimized
Manufacturing process	Variable; stronger if process is necessary for the API or product quality
Packaging and stability claims	Usually supplementary rather than decisive

A generic applicant could change excipients while maintaining the same active ingredient, strength, and immediate-release profile. That makes a conventional excipient list less likely to block entry by itself.

What commercial opportunities exist for excipient suppliers?

The immediate commercial opportunity is recurring supply of standard pharmaceutical excipients for a branded oncology product. Volumes are likely smaller than for mass-market chronic medicines, but oncology products can support premium quality, documentation, and supply-assurance contracts.

Relevant supplier opportunities include:

• Direct supply of mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate
• Film-coating premixes with controlled color and opacity
• Low-peroxide or low-moisture excipient grades
• Excipient supply under dual-source qualification
• Technical support for tablet compression and coating scale-up
• Alternative excipients for generic formulation development
• Taste-masking polymers and suspending agents for lifecycle products
• High-barrier packaging and desiccant systems

The most defensible supplier position comes from regulatory qualification, consistent particle-size distribution, low extractables, supply continuity, and proven performance in the specific compression and coating process. Commodity pricing alone is unlikely to create durable value.

What formulation strategy should generic manufacturers use?

A generic developer should prioritize bioequivalent immediate-release tablets using a formulation that avoids unnecessary similarity to any Orange Book-listed composition claims. The development program should focus on:

• Matching dissolution across physiological pH conditions
• Controlling magnesium stearate level and lubrication time
• Preserving rapid croscarmellose-mediated disintegration
• Achieving content uniformity at low drug loading
• Reproducing tablet hardness and friability
• Maintaining stability under accelerated and long-term conditions
• Using a distinct coating composition where legally advantageous
• Evaluating fed and fasted bioequivalence requirements

The most practical design-around would likely retain common diluents and disintegrants while changing excipient grades, coating composition, ratios, granulation method, or compression parameters. The legal value of that strategy depends on the actual patent claims, not on the commercial ingredient list.

What litigation and settlement risks affect VANFLYTA?

A Paragraph IV challenge could produce litigation over active-ingredient patents, polymorphs, formulations, treatment methods, or dosing regimens. A settlement could establish a licensed launch date before patent expiry, subject to antitrust review and regulatory exclusivity.

No specific VANFLYTA settlement or generic launch date should be treated as established without a public court docket, SEC filing, FDA filing, or company announcement. The key diligence documents are the Orange Book, ANDA litigation complaints, district-court opinions, Federal Circuit decisions, and FDA approval records.[3][4]

Key Takeaways

• VANFLYTA is an immediate-release quizartinib tablet using a conventional excipient system.
• Mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and film-coating materials support a scalable manufacturing platform.
• The strongest lifecycle opportunities are lower-pill-burden tablets, dispersible or liquid dosage forms, pediatric delivery, taste masking, and exposure-control formulations.
• Excipient composition patents may supplement, but are unlikely by themselves to replace, core chemical, salt, polymorph, and method-of-use protection.
• VANFLYTA faces generic rather than biosimilar risk.
• The commercial generic-entry date depends on Orange Book patents, NCE exclusivity, orphan-drug exclusivity, Paragraph IV activity, and any settlement agreement.
• Excipient suppliers can compete through qualified grades, supply security, coating systems, and technical manufacturing support.

FAQs

Is VANFLYTA an immediate-release or extended-release product?

VANFLYTA is an immediate-release, film-coated tablet. The approved product does not use an extended-release matrix or depot delivery system.[1]

Does VANFLYTA contain lactose?

The FDA label identifies mannitol and microcrystalline cellulose as principal diluent materials. Lactose is not identified among the listed inactive ingredients.[1]

Is there a liquid version of quizartinib?

The FDA-approved VANFLYTA product is supplied as tablets. A liquid, suspension, or dispersible version would require separate pharmaceutical development and regulatory support.

Can a generic manufacturer use the same excipients as VANFLYTA?

A generic manufacturer can generally use the same excipients if the resulting product satisfies applicable regulatory requirements and does not infringe enforceable patent claims. The relevant question is the patent claim scope, not whether an excipient is commercially common.

What is the primary commercial risk to VANFLYTA?

The primary long-term risk is ANDA-based generic competition after applicable regulatory exclusivity and patent barriers expire. Earlier risk may arise from competing FLT3-directed therapies, treatment-regimen changes, safety concerns, or reduced use of quizartinib in clinical practice.

References

1. U.S. Food and Drug Administration. (2023). VANFLYTA (quizartinib) prescribing information. Daiichi Sankyo, Inc.

2. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-amendments-and-requests-final-approval-tentatively-approved-andas